Higher expression levels of the MET receptor and of its ligand (hepatocyte growth factor – HGF) have been correlated with advanced stage and poor survival in CRC (Kammula et al., 2007). Both mAbs targeting the MET receptor or HGF ligand and TKIs targeting MET are in clinical investigation ...
The absence of PTEN protein expression is an independent prognostic marker in early stage resected lung adenocarcinoma. Inhibition of the PI3K/AKT/mTOR signal pathway can be an effective strategy to NSCLC harboring the EGFR activating mutations that acquires resistance to both TKIs and radiotherapy due...
FBXW2 is a poorly characterized F-box protein, as a tumor suppressor that inhibits growth and metastasis of lung cancer by promoting ubiquitylation and degradation of oncogenic proteins, including SKP2 and β-catenin. However, what the biological functions of FBXW2 in prostate cancer cells and whe...
there is still a significant unmet medical need for effective therapies for patients who are refractory to current therapies or relapse after standard of care. The EGFR-targeting ADC has the potential to overcome the resistance to EGFR monoclonal antibodies and Tyrosine kinase inhibitors (TKIs)...
These agents or drugs are categorized by their mode of activity within a cell, for example, whether and at what stage they affect the cell cycle. Alternatively, an agent may be characterized based on its ability to directly cross-link DNA, to intercalate into DNA, or to induce chromosomal...
For secondary outcomes of progression-free and overall survival, codon 13 was likewise higher than for other KRAS mutations, but not higher than wild-type.62 Moreover, this area of research remains in a hypothesis-generating stage, and prospective studies in this area are needed.63 • ...
This has a lot about end stage kidney failure so probably not and never will be applicable to you so don’t get worried! Quote Thanks Add post Share Report Bookmark Sunnysideup999 · 24/03/2023 06:51 Did you get any diagnosis of kidney disease when they gave you your results? I’m...
causing over 140 000 deaths every year.1 Although progress has been made in its treatment by improved debulking surgery and the introduction of platinum–taxane regimens, the 5-year survival rate of advanced-stage epithelial ovarian cancer remains below 30%.2 This poor prognosis is mostly related...
Claudin-2 may be involved in the tumor progression of adenocarcinoma because it enhanced cell migration [22] and colonization [23] in A549 cells. Therefore, we examined what regulatory mechanism is involved in the regulation of claudin-2 expression in A549 cells. Claudin-2 protein was detected ...
Gefitinib, a small-molecule inhibitor of EGFR, can improve the survival rate of patients with advanced stage ESCA and is a promising agent for second-line treatment of advanced ESCA, while relatively low response rate and drug resistance hinder its wide clinical application.6,32 To explore the ...